Tyagarajan Seshu's Form 4 filing
Candel Therapeutics, Inc. (CADL) · filed Mar 19, 2025
- Accession no.
- 0000950170-25-042002
- Filed
- Mar 19, 2025
- Trade date
- Mar 17, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $275.9K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0000950170-25-042724 (Mar 20, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tyagarajan SeshuCIK 0001923794 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2025 | Common Stock | SSaleDisposed | −31,278 | $8.82 | −$275,871.96 | 85,512 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2025 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 70,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.